Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival.

BACKGROUND We explored the correlation between serum human epidermal growth factor receptor-2 (HER2) extracellular domain (ECD) and tissue HER2 status, their relationship with clinicopathological parameters and their impact on disease-free survival (DFS) and overall survival in early breast cancer patients. PATIENTS AND METHODS This prospective trial included patients with stage I-III breast cancer. Serum HER2 ECD levels were measured by two enzyme-linked immunosorbent assays before surgical treatment. Tissue HER2 status was analyzed by immunohistochemistry (IHC) in all tumors; FISH assay was utilized in HER2 2+ tumors by IHC. RESULTS From May 2000 to July 2005, 256 consecutive stage I-III breast cancer patients were included in this study. High serum HER2 ECD levels (>or=15 ng/ml) were reported in 23 patients (9.0%) and HER2-positive status in tumor tissue was observed in 42 patients (16.4%) with a concordance of 87.1%. High HER2 ECD levels were significantly associated with high histological grade (P = 0.003), stage III (P = 0.008), lymph node involvement (P = 0.035) and negativity of both estrogen (P = 0.016) and progesterone (P = 0.007) receptors. At multivariate analysis, high serum HER2 ECD levels were a significant independent prognostic factor of worse DFS (P = 0.009). CONCLUSIONS A statistically significant association was observed between high serum HER2 ECD levels and worse DFS in early breast cancer patients.

[1]  B Fisher,et al.  erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. , 1998, Journal of the National Cancer Institute.

[2]  J. Baselga,et al.  Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. , 2001, Cancer research.

[3]  A. Dnistrian,et al.  Monitoring Therapy by Serum HER-2/Neu , 2000, The International journal of biological markers.

[4]  B. Gusterson,et al.  Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[6]  C. Hudis,et al.  Serum HER2 extracellular domain in metastatic breast cancer patients treated with weekly trastuzumab and paclitaxel: association with HER2 status by immunohistochemistry and fluorescence in situ hybridization and with response rate. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  D. Chan,et al.  Clinical utility of serum HER-2/neu testing on the Bayer Immuno 1 automated system in breast cancer. , 2001, Anticancer research.

[8]  R. Mehta,et al.  Plasma c-erbB-2 levels in breast cancer patients: prognostic significance in predicting response to chemotherapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  K. Pantel,et al.  Quantitative assessment of HER-2/neu protein concentration in breast cancer by enzyme-linked immunosorbent assay. , 2003, The International journal of biological markers.

[10]  T. Fehm,et al.  Clinical Utility of Serial Serum c-erbB-2 Determinations in the Follow-up of Breast Cancer Patients , 2002, Breast Cancer Research and Treatment.

[11]  E. Lee,et al.  Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer. , 2006, Clinical chemistry.

[12]  J. Garcia-conde,et al.  Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  R. Colomer,et al.  Does HER-2 status predict only a decreased response to hormone therapy in advanced breast cancer, or does it also predict the extent of metastatic disease? , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Dittadi,et al.  Evaluation of HER-2/neu in Serum and Tissue of Primary and Metastatic Breast Cancer Patients using an Automated Enzyme Immunoassay , 2001, The International journal of biological markers.

[15]  R. Molina,et al.  C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients. , 1999, Anticancer research.

[16]  O. Kallioniemi,et al.  Elevated erbB‐2 oncoprotein levels in preoperative and follow‐up serum samples define an aggressive disease course in patients with breast cancer , 1994, Cancer.

[17]  S. Naber,et al.  Detection and quantitation of the human neu oncoprotein , 1991 .

[18]  E. Perez,et al.  A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  T. Visakorpi,et al.  Association of C‐erbB‐2 protein over‐expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long‐term survival in breast cancer , 1991, International journal of cancer.

[20]  W. Carney,et al.  Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Zeillinger,et al.  Tissue expression and serum levels of HER-2/neu in patients with breast cancer. , 1997, Oncology.

[22]  F Vignon,et al.  [Growth factors and cancer]. , 1994, Journal de gynecologie, obstetrique et biologie de la reproduction.

[23]  Donald L Weaver,et al.  Revision of the American Joint Committee on Cancer staging system for breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  C. Hudis.  Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.

[25]  D. Berry,et al.  c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. , 1994, The New England journal of medicine.

[26]  R. Molina,et al.  Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer. , 2003, Anticancer research.

[27]  R. Neumann,et al.  Serum HER-2 extracellular domain: relationship with clinicobiological presentation and prognostic value before and after primary treatment in 701 breast cancer patients. , 2004, The International journal of biological markers.

[28]  L. Skoog,et al.  c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. , 1995, European journal of cancer.

[29]  G. Steger,et al.  Soluble HER‐2/neu neutralizes biologic effects of anti‐HER‐2/neu antibody on breast cancer cells in vitro , 1997, International journal of cancer.

[30]  A. Bianco,et al.  c-erb B2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.